JP7474289B2 - カリウムチャンネル開口薬としての有用な新規化合物 - Google Patents
カリウムチャンネル開口薬としての有用な新規化合物 Download PDFInfo
- Publication number
- JP7474289B2 JP7474289B2 JP2022122598A JP2022122598A JP7474289B2 JP 7474289 B2 JP7474289 B2 JP 7474289B2 JP 2022122598 A JP2022122598 A JP 2022122598A JP 2022122598 A JP2022122598 A JP 2022122598A JP 7474289 B2 JP7474289 B2 JP 7474289B2
- Authority
- JP
- Japan
- Prior art keywords
- compounds
- chloro
- phenyl
- group
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims description 75
- 229940127315 Potassium Channel Openers Drugs 0.000 title description 3
- 208000016354 hearing loss disease Diseases 0.000 claims description 21
- 206010011878 Deafness Diseases 0.000 claims description 20
- 231100000888 hearing loss Toxicity 0.000 claims description 20
- 230000010370 hearing loss Effects 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 19
- 210000003027 ear inner Anatomy 0.000 claims description 15
- 210000002768 hair cell Anatomy 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 230000001953 sensory effect Effects 0.000 claims description 10
- 210000002985 organ of corti Anatomy 0.000 claims description 9
- 230000006378 damage Effects 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- KFNMYSQMIDOIBM-INIZCTEOSA-N 1-[(1S)-5-chloro-2,3-dihydro-1H-inden-1-yl]-3-(3,4-difluorophenyl)-1-methylurea Chemical compound FC=1C=C(C=CC=1F)NC(N(C)[C@H]1CCC2=CC(=CC=C12)Cl)=O KFNMYSQMIDOIBM-INIZCTEOSA-N 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 24
- 125000001424 substituent group Chemical group 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 208000035475 disorder Diseases 0.000 description 21
- -1 cyclopentathienyl group Chemical group 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 241000124008 Mammalia Species 0.000 description 13
- 229940002612 prodrug Drugs 0.000 description 13
- 239000000651 prodrug Substances 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 231100000199 ototoxic Toxicity 0.000 description 12
- 230000002970 ototoxic effect Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 102000004257 Potassium Channel Human genes 0.000 description 9
- 210000000959 ear middle Anatomy 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 229930027917 kanamycin Natural products 0.000 description 9
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 9
- 229960000318 kanamycin Drugs 0.000 description 9
- 229930182823 kanamycin A Natural products 0.000 description 9
- 108020001213 potassium channel Proteins 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 8
- 229960003883 furosemide Drugs 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 229910052716 thallium Inorganic materials 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 235000013877 carbamide Nutrition 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 239000012948 isocyanate Substances 0.000 description 6
- 238000011200 topical administration Methods 0.000 description 6
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 5
- 210000003477 cochlea Anatomy 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 230000004224 protection Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
- 241000700198 Cavia Species 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 150000002513 isocyanates Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000004310 Ion Channels Human genes 0.000 description 3
- 108090000862 Ion Channels Proteins 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 150000001412 amines Chemical group 0.000 description 3
- 150000001602 bicycloalkyls Chemical group 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 210000000860 cochlear nerve Anatomy 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 210000000067 inner hair cell Anatomy 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 206010011891 Deafness neurosensory Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 150000001448 anilines Chemical class 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000010845 search algorithm Methods 0.000 description 2
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical compound NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 description 2
- 150000003672 ureas Chemical class 0.000 description 2
- KTTBVFVRXDRSSP-OSMZGAPFSA-N (1S,2S,4R)-N-[[3-(pentafluoro-lambda6-sulfanyl)phenyl]methyl]bicyclo[2.2.1]heptane-2-carboxamide Chemical compound FS(C=1C=C(CNC(=O)[C@@H]2[C@H]3CC[C@@H](C2)C3)C=CC=1)(F)(F)(F)F KTTBVFVRXDRSSP-OSMZGAPFSA-N 0.000 description 1
- MDNSLPICAWKNAG-UHFFFAOYSA-N 2-(2,5-dioxopyrrol-1-yl)propanoic acid Chemical compound OC(=O)C(C)N1C(=O)C=CC1=O MDNSLPICAWKNAG-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- HLYWMGQODAGAFU-INIZCTEOSA-N 3-(3,4-difluorophenyl)-1-[(1S)-5-fluoro-2,3-dihydro-1H-inden-1-yl]-1-methylurea Chemical compound CN([C@H]1CCc2cc(F)ccc12)C(=O)Nc1ccc(F)c(F)c1 HLYWMGQODAGAFU-INIZCTEOSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- FBCXLUDELSDWOT-UHFFFAOYSA-N 4-chloro-N-[[4-(pentafluoro-lambda6-sulfanyl)phenyl]methyl]benzamide Chemical compound ClC1=CC=C(C(=O)NCC2=CC=C(C=C2)S(F)(F)(F)(F)F)C=C1 FBCXLUDELSDWOT-UHFFFAOYSA-N 0.000 description 1
- XZOBPCYHLAFDGI-UHFFFAOYSA-N 4-chloro-n-[[4-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=O)C1=CC=C(Cl)C=C1 XZOBPCYHLAFDGI-UHFFFAOYSA-N 0.000 description 1
- NUJKNXFBLODMFO-UHFFFAOYSA-N 4-fluoro-N-[[4-(pentafluoro-lambda6-sulfanyl)phenyl]methyl]benzamide Chemical compound FC1=CC=C(C(=O)NCC2=CC=C(C=C2)S(F)(F)(F)(F)F)C=C1 NUJKNXFBLODMFO-UHFFFAOYSA-N 0.000 description 1
- YKQAWQITONYURX-UHFFFAOYSA-N 4-fluoro-n-[[4-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound C1=CC(F)=CC=C1C(=O)NCC1=CC=C(C(F)(F)F)C=C1 YKQAWQITONYURX-UHFFFAOYSA-N 0.000 description 1
- VUSRBXBBIVFUBF-UHFFFAOYSA-N 5-chloro-N-[[4-(pentafluoro-lambda6-sulfanyl)phenyl]methyl]thiophene-2-carboxamide Chemical compound ClC1=CC=C(S1)C(=O)NCC1=CC=C(C=C1)S(F)(F)(F)(F)F VUSRBXBBIVFUBF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000000781 Conductive Hearing Loss Diseases 0.000 description 1
- 206010010280 Conductive deafness Diseases 0.000 description 1
- FTNZQPFRUAPXLA-JOXAXOLPSA-N FC(OC=1C=C(CNC(=O)[C@@H]2[C@H]3CC[C@@H](C2)C3)C=CC1)(F)F.FC(C=1C=C(CNC(=O)[C@@H]3[C@H]2CC[C@@H](C3)C2)C=CC1)(F)F Chemical compound FC(OC=1C=C(CNC(=O)[C@@H]2[C@H]3CC[C@@H](C2)C3)C=CC1)(F)F.FC(C=1C=C(CNC(=O)[C@@H]3[C@H]2CC[C@@H](C3)C2)C=CC1)(F)F FTNZQPFRUAPXLA-JOXAXOLPSA-N 0.000 description 1
- WUEYHEWZJHADIM-QSZVZPBDSA-N FC=1C=C(C=CC1F)NC(N(C)[C@H]1CCC2=CC(=CC=C12)Cl)=O.FC=1C=C(C=CC1F)NC(N(C)[C@H]1CCC2=CC=CC=C12)=O Chemical compound FC=1C=C(C=CC1F)NC(N(C)[C@H]1CCC2=CC(=CC=C12)Cl)=O.FC=1C=C(C=CC1F)NC(N(C)[C@H]1CCC2=CC=CC=C12)=O WUEYHEWZJHADIM-QSZVZPBDSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000000258 High-Frequency Hearing Loss Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 206010061373 Sudden Hearing Loss Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- NEEHYRZPVYRGPP-IYEMJOQQSA-L calcium gluconate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O NEEHYRZPVYRGPP-IYEMJOQQSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical group 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 208000023563 conductive hearing loss disease Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 201000002664 drug-induced hearing loss Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000885 high-frequency hearing loss Toxicity 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 description 1
- 229960002140 medetomidine Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000008587 neuronal excitability Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000004036 potassium channel stimulating agent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- MSXHSNHNTORCAW-GGLLEASOSA-M sodium;(2s,3s,4s,5r,6s)-3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].O[C@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O MSXHSNHNTORCAW-GGLLEASOSA-M 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 125000005751 substituted indanyl group Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 210000003454 tympanic membrane Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/26—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/40—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/43—Y being a hetero atom
- C07C323/44—X or Y being nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/63—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Description
本発明は、一般式(I):
n=0又は1であり、
RLが、非置換又は置換シクロアルキル基、好ましくは、ビシクロアルキル基、非置換又は置換フェニル基、非置換又は置換チエニル基又はシクロペンタチエニル基及び非置換又は置換インダニル基からなる群から選択され、これは、任意にヘテロ原子を含み、及び
RRが、非置換若しくは置換フェニル基又は非置換若しくは置換ベンジル基からなる群から選択される置換基であり、これは、任意にヘテロ原子を含む)
で表される新規化合物、又はその立体異性体、互変異性体、プロドラッグ若しくは塩、好ましくはその医薬的に許容される塩を提供する。
- これらの化合物において置換基RLが、フェニル基又はシクロアルキル基又はシクロペンタチエニル基又はインダニル基から選択される場合、及びこれらの化合物において置換基RRが、上記の第1の置換基群からの置換基で置換されている場合、本発明の化合物が好ましい。
- これらの化合物において置換基RLが、チエニル基である場合、及びこれらの化合物において置換基RRが、上記の第1の置換基の群又は上記の第2の置換基の群からの置換基で置換されている場合、本発明の化合物が好ましい。
- これらの化合物において置換基RLが、シクロアルキル基又はビシクロアルキル基から選択される場合、及び置換基RRが、上記の第2の置換基群からの置換基で置換される場合、本発明の化合物が好ましい。
(1R,2R,4S)-レル-N-(3-(ペンタフルオロスルファニル)ベンジル)ビシクロ[2.2.1]ヘプタン-2-カルボキサミド
(1S,2S,4R)-N-(3-(ペンタフルオロスルファニル)ベンジル)ビシクロ[2.2.1]ヘプタン-2-カルボキサミド
(1R,2R,4S)-レル-N-(3-(トリフルオロメチル)ベンジル)ビシクロ[2.2.1]ヘプタン-2-カルボキサミド
(1R,2R,4S)-レル-N-(3-(トリフルオロメトキシ)ベンジル)ビシクロ[2.2.1]ヘプタン-2-カルボキサミド
(1S,2S,4R)-N-(3-(トリフルオロメチル)ベンジル)ビシクロ[2.2.1]ヘプタン-2-カルボキサミド
(1S,2S,4R)-N-(3-(トリフルオロメトキシ)ベンジル)ビシクロ[2.2.1]ヘプタン-2-カルボキサミド
(1S,2R,4R)-レル-2-(ビシクロ[2.2.1]ヘプタン-2-イル-N-(2-メチル-4-(ピロリジン-1-イル-フェニル)アセトアミド
(1S,2R,4R)-2-(ビシクロ[2.2.1]ヘプタン-2-イル-N-(2-メチル-4-(ピロリジン-1-イル-フェニル)アセトアミド
(1S,2R,4R)-レル-2-(ビシクロ[2.2.1]ヘプタン-2-イル-N-(2,6-ジメチル-4-(ジメチルアミノ-フェニル)アセトアミド
(1S,2R,4R)-2-(ビシクロ[2.2.1]ヘプタン-2-イル-N-(2,6-ジメチル-4-(ジメチルアミノ-フェニル)アセトアミド
(1S,2R,4R)-レル-2-(ビシクロ[2.2.1]ヘプタン-2-イル-N-(2,6-ジメチル-4-(ピロリジン-1-イル-フェニル)アセトアミド
(1S,2R,4R)-2-(ビシクロ[2.2.1]ヘプタン-2-イル-N-(2,6-ジメチル-4-(ピロリジン-1-イル-フェニル)アセトアミド
(1S,2R,4R)-レル-2-(ビシクロ[2.2.1]ヘプタン-2-イル-N-(2-メチル-4-(ジメチルアミノ-フェニル)アセトアミド
(1S,2R,4R)-2-(ビシクロ[2.2.1]ヘプタン-2-イル-N-(2-メチル-4-(ジメチルアミノ-フェニル)アセトアミド、であり、
ここで、以下の化合物がさらに好ましい:
- (1R,2R,4S)-レル-N-(3-(ペンタフルオロスルファニル)ベンジル)ビシクロ[2.2.1]ヘプタン-2-カルボキサミド
- (1S,2S,4R)-N-(3-(ペンタフルオロスルファニル)ベンジル)ビシクロ[2.2.1]ヘプタン-2-カルボキサミド
- (1S,2S,4R)-N-(3-(トリフルオロメチル)ベンジル)ビシクロ[2.2.1]ヘプタン-2-カルボキサミド
- (1S,2S,4R)-N-(3-(トリフルオロメトキシ)ベンジル)ビシクロ[2.2.1]ヘプタン-2-カルボキサミド
- (1S,2R,4R)-2-(ビシクロ[2.2.1]ヘプタン-2-イル-N-(2-メチル-4-(ピロリジン-1-イル-フェニル)アセトアミド
- (1S,2R,4R)-2-(ビシクロ[2.2.1]ヘプタン-2-イル-N-(2,6-ジメチル-4-(ジメチルアミノ-フェニル)アセトアミド
- (1S,2R,4R)-2-(ビシクロ[2.2.1]ヘプタン-2-イル-N-(2,6-ジメチル-4-(ピロリジン-1-イル-フェニル)アセトアミド
- (1S,2R,4R)-2-(ビシクロ[2.2.1]ヘプタン-2-イル-N-(2-メチル-4-(ジメチルアミノ-フェニル)アセトアミド。
p-クロロ-N-(4-トリフルオロメトキシ)ベンジル)ベンズアミド
p-クロロ-N-(4-(ペンタフルオロスルファニル)ベンジル)ベンズアミド
p-フルオロ-N-(4-トリフルオロメトキシ)ベンジル)ベンズアミド
p-フルオロ-N-(4-(ペンタフルオロスルファニル)ベンジル)ベンズアミド
p-クロロ-N-(4-(トリフルオロメチル)ベンジル)ベンズアミド
p-フルオロ-N-(4-(トリフルオロメチル)ベンジル)ベンズアミド、であり、
ここで、以下の化合物がさらに好ましい、
- p-クロロ-N-(4-(ペンタフルオロスルファニル)ベンジル)ベンズアミド
- p-フルオロ-N-(4-(ペンタフルオロスルファニル)ベンジル)ベンズアミド。
5-クロロ-N-(4-トリフルオロメトキシ)ベンジル)チオフェン-2-カルボキサミド
5-フルオロ-N-(4-トリフルオロメトキシ)ベンジル)チオフェン-2-カルボキサミド
5-クロロ-N-(4-(ペンタフルオロスルファニル)ベンジル)チオフェン-2-カルボキサミド
5-フルオロ-N-(4-(ペンタフルオロスルファニル)ベンジル)チオフェン-2-カルボキサミド
5-フルオロ-N-(4-(triフルオロメチル)ベンジル)チオフェン-2-カルボキサミド
5-クロロ-N-(4-(triフルオロメチル)ベンジル)チオフェン-2-カルボキサミド
N-(2,6-ジメチル-4-(ピロリジン-1-イル)-フェニル)-2-(チオフェン-2-イル)アセトアミド
N-(2-メチル-4-(ピロリジン-1-イル)-フェニル)-2-(チオフェン-2-イル)アセトアミド
N-(2,6-ジメチル-4-(ピロリジン-1-イル)フェニル)-2-(5-クロロ-チオフェン-2-イル)アセトアミド
N-(2-メチル-4-(ピロリジン-1-イル)-フェニル)-2-(5-クロロ-チオフェン-2-イル)アセトアミド
N-(2,6-ジメチル-4-(ピロリジン-1-イル)-フェニル)-2-(5-フルオロ-チオフェン-2-イル)アセトアミド
N-(2-メチル-4-(ピロリジン-1-イル)-フェニル)-2-(5-フルオロ-チオフェン-2-イル)アセトアミド
N-(2,6-ジメチル-4-(ジメチルアミノ-1-イル)-フェニル)-2-(チオフェン-2-イル)アセトアミド
N-(2-メチル-4-(ジメチルアミノ-1-イル)-フェニル)-2-(チオフェン-2-イル)アセトアミド
N-(2,6-ジメチル-4-(ジメチルアミノ-1-イル)フェニル)-2-(5-クロロ-チオフェン-2-イル)アセトアミド
N-(2-メチル-4-(ジメチルアミノ-1-イル)-フェニル)-2-(5-クロロ-チオフェン-2-イル)アセトアミド
N-(2,6-ジメチル-4-(ジメチルアミノ-1-イル)-フェニル)-2-(5-フルオロ-チオフェン-2-イル)アセトアミド
N-(2-メチル-4-(ジメチルアミノ-1-イル)-フェニル)-2-(5-フルオロ-チオフェン-2-イル)アセトアミド
N-(2,6-ジメチル-4-(モルフォリノ-1-イル)-フェニル)-2-(チオフェン-2-イル)アセトアミド
N-(2,6-ジメチル-4-(モルフォリノ-1-イル)-フェニル)-2-(5-フルオロ-チオフェン-2-イル)アセトアミド
N-(2,6-ジメチル-4-(モルフォリノ-1-イル)-フェニル)-2-(5-クロロ-チオフェン-2-イル)アセトアミド
(S)-3-(3,4-ジフルオロフェニル)-1-(2-クロロ-5,6-ジヒドロ-4H-シクロペンタ[b]チオフェン-6-イル)-1-メチルウレア
(S)-3-(3-ペンタフルオロスルファニルフェニル)-1-(2-クロロ-5,6-ジヒドロ-4H-シクロペンタ[b]チオフェン-6-イル)-1-メチルウレア、であり、
ここで、以下の化合物がさらに好ましい:
- 5-クロロ-N-(4-(ペンタフルオロスルファニル)ベンジル)チオフェン-2-カルボキサミド
- 5-フルオロ-N-(4-(ペンタフルオロスルファニル)ベンジル)チオフェン-2-カルボキサミド
- N-(2,6-ジメチル-4-(ピロリジン-1-イル)フェニル)-2-(5-クロロ-チオフェン-2-イル)アセトアミド
- (S)-3-(3,4-ジフルオロフェニル)-1-(2-クロロ-5,6-ジヒドロ-4H-シクロペンタ[b]チオフェン-6-イル)-1-メチルウレア
- (S)-3-(3-ペンタフルオロスルファニルフェニル)-1-(2-クロロ-5,6-ジヒドロ-4H-シクロペンタ[b]チオフェン-6-イル)-1-メチルウレア
(S)-3-(3,4-ジフルオロフェニル)-1-(2,3-ジヒドロ-1H-インデン-1イル)-1-メチルウレア
(S)-3-(3,4-ジフルオロフェニル)-1-(5-クロロ-2,3-ジヒドロ-1H-インデン-1イル)-1-メチルウレア
(S)-3-(3,4-ジフルオロフェニル)-1-(5-フルオロ-2,3-ジヒドロ-1H-インデン-1イル)-1-メチルウレア
(S)-1-(5-クロロ-2,3-ジヒドロ-1-H-インデン-1-イル)-1-メチル-3-(3-ペンタフルオロスルファニルフェニル)ウレア、であり、
ここで、以下の化合物がさらに好ましい:
- (S)-3-(3,4-ジフルオロフェニル)-1-(5-クロロ-2,3-ジヒドロ-1H-インデン-1イル)-1-メチルウレア
- (S)-1-(5-クロロ-2,3-ジヒドロ-1-H-インデン-1-イル)-1-メチル-3-(3-ペンタフルオロスルファニルフェニル)ウレア。
- 上記で請求され及び定義された少なくとも1つの本発明の化合物、及び
- 医薬的に許容される担体又は希釈剤。
- 前記障害が、異常なカリウムチャンネル活性に関連する障害、特にコルチ器官における損傷後の内耳難聴又は感覚有毛細胞の喪失を含み、及び
- 前記方法が、前記哺乳動物に治療上有効量の請求項に記載の化合物及び上記で定義された化合物を投与することを含む。
- 哺乳動物において障害の状態が発生することを防ぐこと、例えば、前記哺乳動物が、その障害に罹りやすいが、その障害を有すると診断されていない等、
- 障害の状態を阻害すること、すなわち、さらなる発達を止めること、及び/又は
- 障害の状態を緩和すること、すなわち、障害の症状を改善すること。
1. 対応する炭素環式酸(0.5mmol)が、3mlの乾燥ジメチルホルムアミド(DMF)、に溶解され、及びジイソプロピルエチルアミン(1.5mmol)及びカップリング剤HATU[O-N,N,N’,N’-テトラメチルウロニウム-ヘキサフルオロフォスファト](0.55mmol)が加えられた。混合物は、15分間攪拌され、対応するアミン(0.55mmol)が加えられた。得られた反応物は、さらに4~16時間攪拌され、その反応の完了は、TLC(薄層クロマトグラフィー)又はLC-MS(液体クロマトグラフィー-質量分析)で制御された。混合物は、25mlの酢酸エチル(EtOAc)で希釈され、20mlのブラインで1回洗浄され、20mlの飽和NaHCO3溶液で1回洗浄され、20mlの5%クエン酸溶液で3回洗浄され、及び再度20mlの飽和NaHCO3溶液で1回洗浄され、無水Na2SO4で乾燥され、そして真空中で濃縮された。得られた残渣は、フラッシュクロマトグラフィー(典型的に石油エーテル-EtOAc系を用いる)及び/又は結晶化及び/又は必要な場合、逆相分取HPLCにより精製された。
5mlのジクロロメタン及び5mlの水の混合物に、(対応する)置換アニリン(0.5mmol)、NaHCO3(100mg、1.2mmol)及び59mg(0.2mmol)のトリホスゲンが順次加えられた。得られた反応混合物は、30分間激しく攪拌され、ジクロロメタン層が、10mlのブラインで2回洗浄され、MgSO4上で短時間乾燥され、そして対応するウレアの合成のためにイソシアネートストック溶液として使用された。
(対応する)置換アニリン(0.5mmol)が、2.5mlのジメチルスルホキシド(DMSO)に溶解され、そしてカルボニルジイミダゾール(100mg、0.6mmol)が加えられた。溶液は、室温で2時間攪拌され、対応するウレアの合成に直接使用された。
Kv7.4活性化は、機能的Kv7.4細胞株及びタリウム感受性蛍光色素を用いることによってFLIPRTetra(モレキュラーデバイス製のハイスループットセルラースクリーニングシステム、LLC、米国)で測定された。アッセイの原理は、タリウムに対するカリウムチャネルの浸透性に基づく。タリウムの侵入は、Kv7.4コード遺伝子で安定にトランスフェクトされたCHO細胞(チャイニーズハムスター卵巣細胞)において測定された。細胞は、この段階ではプロ蛍光色素であるThallos(商標)色素(TEFLABS、cat.♯0913)が充填された。チャネル活性化後、タリウムを含有する細胞外溶液で、タリウムイオンは、細胞膜を横切って開いたカリウムチャンネルを通って濃度勾配を下に移動する。タリウムイオンが、Thallos(商標)色素に結合すると、490nmでの励起により515nmで明るい蛍光を発する。重要なことに、測定された蛍光発生シグナルは、タリウムを透過するイオンチャンネルの活性を定量的に反映する。
1. 384ウェルプレート(黒色の壁、透明な底)に10.000c/wで細胞を播種する。
2. 播種の24時間後、手動で培地を排出し、製造元の指示に従って調製された20μL/wの0.5×Thallos(商標)感受性色素を加えた。
3. 細胞を1時間、室温でインキュベートする。
4. タリウムフリー、塩化物フリーのタイロードバッファー(5mM D-グルコネートカリウム、130mM D-グルコネートナトリウム、2mMD-グルコネートカルシウム、5mM NaHCO3、1mMD-グルコネートマグネシウム、20mM HEPES、pH7.4)2.5%DMSO(最終DMSOは、0.5%である)で5倍濃縮されたテスト化合物を5μL/ウェルのオフラインで注入する。
5. 10分間インキュベーションした後、FLIPRTetraで25μL/ウェルの2×濃縮タリウムEC20(5mM)を注入し、動的応答(kinetic response)を120秒間モニターする。
本発明の化合物はまた、インビボでテストされた。これに関連して、聴覚神経の複合活動電位(CAP)を繰り返し記録するために、モルモットの正円窓小窩に永久金電極が、両側に移植された。正円窓は、中耳から内耳への開口部である。金電極は、頭蓋骨の小型プラグに接続された。実験の間、オージオグラムは、オクターブ当たり8ステップの分解能で、0.5~45.6kHzの間で決定された。自動閾値検索アルゴリズムが適用された。
Claims (5)
- 以下の化合物:
(S)-3-(3,4-ジフルオロフェニル)-1-(5-クロロ-2,3-ジヒドロ-1H-インデン-1イル)-1-メチルウレア。 - - 請求項1に記載の化合物、及び
- 医薬的に許容される担体又は希釈剤
を含む医薬組成物又は医薬。 - コルチ器官の感覚有毛細胞の損傷又は喪失後の内耳難聴の予防または治療のための、医薬組成物または医薬として使用するための、請求項1に記載の化合物。
- コルチ器官の感覚有毛細胞の損傷又は喪失後の内耳難聴の予防または治療のための、活性成分として((S)-3-(3,4-ジフルオロフェニル)-1-(5-クロロ-2,3-ジヒドロ-1H-インデン-1イル)-1-メチルウレアを含む医薬組成物または医薬。
- コルチ器官の感覚有毛細胞の損傷又は喪失後の内耳難聴の予防または治療のための医薬組成物または医薬の調製のための、(S)-3-(3,4-ジフルオロフェニル)-1-(5-クロロ-2,3-ジヒドロ-1H-インデン-1イル)-1-メチルウレアの使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17158326.3 | 2017-02-28 | ||
EP17158326.3A EP3366683A1 (en) | 2017-02-28 | 2017-02-28 | Cyclic amides, acteamides and ureas useful as potassium channel openers |
JP2020163507A JP2021008479A (ja) | 2017-02-28 | 2020-09-29 | カリウムチャンネル開口薬としての有用な新規化合物 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020163507A Division JP2021008479A (ja) | 2017-02-28 | 2020-09-29 | カリウムチャンネル開口薬としての有用な新規化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022166055A JP2022166055A (ja) | 2022-11-01 |
JP7474289B2 true JP7474289B2 (ja) | 2024-04-24 |
Family
ID=58192162
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019567399A Active JP6795713B2 (ja) | 2017-02-28 | 2018-02-27 | カリウムチャンネル開口薬としての有用な新規化合物 |
JP2020163507A Withdrawn JP2021008479A (ja) | 2017-02-28 | 2020-09-29 | カリウムチャンネル開口薬としての有用な新規化合物 |
JP2022122598A Active JP7474289B2 (ja) | 2017-02-28 | 2022-08-01 | カリウムチャンネル開口薬としての有用な新規化合物 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019567399A Active JP6795713B2 (ja) | 2017-02-28 | 2018-02-27 | カリウムチャンネル開口薬としての有用な新規化合物 |
JP2020163507A Withdrawn JP2021008479A (ja) | 2017-02-28 | 2020-09-29 | カリウムチャンネル開口薬としての有用な新規化合物 |
Country Status (24)
Country | Link |
---|---|
US (2) | US11034665B2 (ja) |
EP (3) | EP3366683A1 (ja) |
JP (3) | JP6795713B2 (ja) |
KR (2) | KR102443685B1 (ja) |
CN (2) | CN114105942A (ja) |
AU (2) | AU2018227005B2 (ja) |
BR (2) | BR122020025103B1 (ja) |
CA (1) | CA3052359A1 (ja) |
CL (2) | CL2019002445A1 (ja) |
CY (2) | CY1123114T1 (ja) |
DK (2) | DK3484863T3 (ja) |
ES (2) | ES2846772T3 (ja) |
HR (2) | HRP20201159T1 (ja) |
HU (2) | HUE051854T2 (ja) |
IL (1) | IL268931B (ja) |
LT (2) | LT3484863T (ja) |
MX (2) | MX2020010866A (ja) |
PH (1) | PH12019550146A1 (ja) |
PL (2) | PL3484863T3 (ja) |
PT (2) | PT3484863T (ja) |
RS (2) | RS60648B1 (ja) |
SI (2) | SI3567034T1 (ja) |
WO (1) | WO2018158256A2 (ja) |
ZA (1) | ZA201905198B (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3366683A1 (en) | 2017-02-28 | 2018-08-29 | Acousia Therapeutics GmbH | Cyclic amides, acteamides and ureas useful as potassium channel openers |
KR20230004785A (ko) | 2020-04-29 | 2023-01-06 | 이도르시아 파마슈티컬스 리미티드 | 스피로우레아 유도체 |
TW202216660A (zh) | 2020-06-25 | 2022-05-01 | 瑞士商愛杜西亞製藥有限公司 | 環丁基-脲衍生物 |
AU2021380914A1 (en) * | 2020-11-19 | 2023-06-22 | Acousia Therapeutics Gmbh | Non-aqueous gel composition |
EP4279061A1 (en) * | 2022-05-18 | 2023-11-22 | Acousia Therapeutics GmbH | Aqueous gel composition |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003503385A (ja) | 1999-06-25 | 2003-01-28 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | インダニル置換ベンゼンカルボキサミド、その製造方法、薬剤としてのその使用およびそれを含有する医薬処方物 |
WO2010139481A1 (en) | 2009-06-04 | 2010-12-09 | Merz Pharma Gmbh & Co. Kgaa | Glycine b antagonists |
JP2013540750A (ja) | 2010-09-22 | 2013-11-07 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 置換されたベンズアミド化合物 |
JP2021008479A (ja) | 2017-02-28 | 2021-01-28 | アコージア セラピューティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | カリウムチャンネル開口薬としての有用な新規化合物 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0594034A (ja) | 1990-06-29 | 1993-04-16 | Xerox Corp | クラツクのない電子写真画像形成デバイス |
EP0957099B1 (en) * | 1998-04-15 | 2002-11-20 | Pfizer Products Inc. | Heterocyclic carboxamides |
DE10061876A1 (de) * | 2000-12-12 | 2002-06-20 | Aventis Pharma Gmbh | Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
US20020183395A1 (en) | 2001-04-04 | 2002-12-05 | Wyeth | Methods for treating hyperactive gastric motility |
US7273866B2 (en) * | 2002-12-20 | 2007-09-25 | Bristol-Myers Squibb Company | 2-aryl thiazole derivatives as KCNQ modulators |
BRPI0408437A (pt) | 2003-03-21 | 2006-04-04 | Lundbeck & Co As H | derivados de p-diaminobenzeno substituìdos, composição farmacêutica, e, uso da mesma |
TWI349666B (en) | 2004-03-12 | 2011-10-01 | Lundbeck & Co As H | Substituted morpholine and thiomorpholine derivatives |
UA89503C2 (uk) | 2004-09-13 | 2010-02-10 | Х. Луннбек А/С | Заміщені похідні аніліну |
US20060188445A1 (en) | 2005-02-22 | 2006-08-24 | Fred Hutchinson Cancer Research Center | Assay for compounds that protect against sensory hair cell death and compounds identified by same |
US7790770B2 (en) | 2005-11-23 | 2010-09-07 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
WO2007087424A2 (en) | 2006-01-25 | 2007-08-02 | The Johns Hopkins University | Method of treating kcnq related disorders using organozinc compounds |
WO2007138112A2 (en) | 2006-06-01 | 2007-12-06 | Devgen N.V. | Compounds that interact with ion channels, in particular with ion channels from the kv family |
US20090118274A1 (en) | 2007-02-15 | 2009-05-07 | Darin Allen | Monocyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
DE102007032436B4 (de) | 2007-07-10 | 2009-07-16 | Heraeus Electro-Nite International N.V. | Vorrichtung zum Sammeln von Gasen in Metallschmelzen |
BRPI0814180A2 (pt) * | 2007-08-01 | 2015-01-27 | Lundbeck & Co As H | Método para reduzir os sintomas de, ou para tratar, um ou mais distúrbios nos quais o sistema dopaminérgico está desregulado |
BRPI0818581A2 (pt) | 2007-10-17 | 2015-07-21 | Sanofi Aventis | Carboxamidas n-fenil-bipirrolidina substituídas e uso terapêutico das mesmas |
WO2009075874A1 (en) * | 2007-12-13 | 2009-06-18 | Amgen Inc. | Gamma secretase modulators |
US7786171B2 (en) * | 2008-04-04 | 2010-08-31 | Abbott Laboratories | Amide derivatives as positive allosteric modulators and methods of use thereof |
TW201038572A (en) | 2009-03-25 | 2010-11-01 | Gruenenthal Gmbh | Substituted spiro-amide compounds |
WO2011085351A2 (en) | 2010-01-11 | 2011-07-14 | The Johns Hopkins University | Method of treating kcnq related disorders |
DE102010007281A1 (de) | 2010-02-08 | 2011-08-11 | EMC microcollections GmbH, 72070 | Neue Aminoalkyl-oxazol- und Aminoalkyl-thiazolcarbonsäureamide und ihre Anwendung zur Stimulation der endogenen situ Regeneration von Haarsinneszellen im Corti'schen Organ des Innenohres beim Säuger |
US8586604B2 (en) * | 2010-08-20 | 2013-11-19 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
WO2013126856A1 (en) * | 2012-02-23 | 2013-08-29 | Vanderbilt University | Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
EP2900674B1 (en) | 2012-09-28 | 2017-05-31 | University of Washington through its Center for Commercialization | Compounds and methods for preventing, treating and/or protecting against sensory hair cell death |
WO2014079850A1 (en) * | 2012-11-23 | 2014-05-30 | F. Hoffmann-La Roche Ag | Substituted heterocyclic derivatives |
PL404138A1 (pl) * | 2013-05-31 | 2014-12-08 | Warszawski Uniwersytet Medyczny | Pochodne kwasu benzoesowego jako inhibitory receptora IL-15Rα |
US20150126507A1 (en) * | 2013-09-05 | 2015-05-07 | Fate Therapeutics, Inc. | Compounds to treat hearing loss |
MX2016005128A (es) * | 2013-11-05 | 2016-07-18 | Hoffmann La Roche | Derivados de 5,6,7,8-tetahidro-5,8-metanocinolina como moduladores del receptor huerfano y relacionado con acido retinoico (rorc) para el tratamiento de enfermedades autoinmunes. |
EP2871181B1 (en) * | 2013-11-12 | 2016-10-05 | Acousia Therapeutics GmbH | Novel Compounds for Regeneration of Terminally-Differentiated Cells and tissues |
CN105017085B (zh) | 2014-04-28 | 2018-06-29 | 中国科学院上海药物研究所 | 一类kcnq钾通道激动剂、其制备方法和用途 |
CN107438613B (zh) * | 2015-02-06 | 2020-08-25 | 华盛顿大学 | 用于预防或治疗感觉毛细胞死亡的化合物和方法 |
GB201601301D0 (en) | 2016-01-25 | 2016-03-09 | Takeda Pharmaceutical | Novel compounds |
-
2017
- 2017-02-28 EP EP17158326.3A patent/EP3366683A1/en not_active Withdrawn
-
2018
- 2018-02-27 PL PL18707374T patent/PL3484863T3/pl unknown
- 2018-02-27 WO PCT/EP2018/054820 patent/WO2018158256A2/en active Application Filing
- 2018-02-27 PT PT187073747T patent/PT3484863T/pt unknown
- 2018-02-27 JP JP2019567399A patent/JP6795713B2/ja active Active
- 2018-02-27 DK DK18707374.7T patent/DK3484863T3/da active
- 2018-02-27 MX MX2020010866A patent/MX2020010866A/es unknown
- 2018-02-27 ES ES19179900T patent/ES2846772T3/es active Active
- 2018-02-27 PL PL19179900T patent/PL3567034T3/pl unknown
- 2018-02-27 AU AU2018227005A patent/AU2018227005B2/en active Active
- 2018-02-27 US US16/487,933 patent/US11034665B2/en active Active
- 2018-02-27 MX MX2019010169A patent/MX2019010169A/es unknown
- 2018-02-27 ES ES18707374T patent/ES2813064T3/es active Active
- 2018-02-27 EP EP19179900.6A patent/EP3567034B1/en active Active
- 2018-02-27 CN CN202111376413.6A patent/CN114105942A/zh active Pending
- 2018-02-27 RS RS20200895A patent/RS60648B1/sr unknown
- 2018-02-27 PT PT191799006T patent/PT3567034T/pt unknown
- 2018-02-27 KR KR1020217035304A patent/KR102443685B1/ko active IP Right Grant
- 2018-02-27 RS RS20201546A patent/RS61254B1/sr unknown
- 2018-02-27 BR BR122020025103-4A patent/BR122020025103B1/pt active IP Right Grant
- 2018-02-27 HU HUE18707374A patent/HUE051854T2/hu unknown
- 2018-02-27 LT LTEP18707374.7T patent/LT3484863T/lt unknown
- 2018-02-27 DK DK19179900.6T patent/DK3567034T3/da active
- 2018-02-27 CN CN201880014217.4A patent/CN110312710B/zh active Active
- 2018-02-27 EP EP18707374.7A patent/EP3484863B1/en active Active
- 2018-02-27 KR KR1020197023369A patent/KR102382795B1/ko active IP Right Grant
- 2018-02-27 SI SI201830189T patent/SI3567034T1/sl unknown
- 2018-02-27 LT LTEP19179900.6T patent/LT3567034T/lt unknown
- 2018-02-27 CA CA3052359A patent/CA3052359A1/en active Pending
- 2018-02-27 SI SI201830113T patent/SI3484863T1/sl unknown
- 2018-02-27 HU HUE19179900A patent/HUE052703T2/hu unknown
- 2018-02-27 BR BR112019017184-3A patent/BR112019017184B1/pt active IP Right Grant
-
2019
- 2019-08-06 ZA ZA2019/05198A patent/ZA201905198B/en unknown
- 2019-08-19 PH PH12019550146A patent/PH12019550146A1/en unknown
- 2019-08-26 CL CL2019002445A patent/CL2019002445A1/es unknown
- 2019-08-26 IL IL268931A patent/IL268931B/en unknown
-
2020
- 2020-07-09 CY CY20201100634T patent/CY1123114T1/el unknown
- 2020-07-23 HR HRP20201159TT patent/HRP20201159T1/hr unknown
- 2020-09-29 JP JP2020163507A patent/JP2021008479A/ja not_active Withdrawn
- 2020-11-09 CY CY20201101052T patent/CY1123488T1/el unknown
- 2020-12-07 HR HRP20201961TT patent/HRP20201961T1/hr unknown
-
2021
- 2021-05-11 US US17/316,823 patent/US11884642B2/en active Active
- 2021-05-12 CL CL2021001243A patent/CL2021001243A1/es unknown
- 2021-10-22 AU AU2021254653A patent/AU2021254653B2/en active Active
-
2022
- 2022-08-01 JP JP2022122598A patent/JP7474289B2/ja active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003503385A (ja) | 1999-06-25 | 2003-01-28 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | インダニル置換ベンゼンカルボキサミド、その製造方法、薬剤としてのその使用およびそれを含有する医薬処方物 |
WO2010139481A1 (en) | 2009-06-04 | 2010-12-09 | Merz Pharma Gmbh & Co. Kgaa | Glycine b antagonists |
JP2013540750A (ja) | 2010-09-22 | 2013-11-07 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 置換されたベンズアミド化合物 |
JP2021008479A (ja) | 2017-02-28 | 2021-01-28 | アコージア セラピューティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | カリウムチャンネル開口薬としての有用な新規化合物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7474289B2 (ja) | カリウムチャンネル開口薬としての有用な新規化合物 | |
US20130224151A1 (en) | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain | |
US20230123729A1 (en) | Compositions and methods for treating neurodegenerative diseases | |
US20210130299A1 (en) | Kv7 channel activators compositions and methods of use | |
RU2779111C2 (ru) | Новые соединения, используемые в качестве открывателей калиевых каналов | |
RU2779131C2 (ru) | Новые соединения, используемые в качестве открывателей калиевых каналов | |
JP2005511639A (ja) | 虚血性疾患の治療用ドパミン再取り込み阻害活性を有するトロパン誘導体 | |
BR112020007787A2 (pt) | inibidores ret9 e vegfr2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220801 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220801 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230801 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231024 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240402 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240412 |